Quanterix ROA 2016-2018 | QTRX
Current and historical return on assets (ROA) values for Quanterix (QTRX) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Quanterix ROA for the three months ending June 30, 2018 was 0.00%.
| Quanterix Annual ROA | |
|---|---|
| 2017 | -29.44 |
| 2016 | -62.43 |
| 2015 | -216.88 |
| Quanterix Quarterly ROA | |
|---|---|
| Q2 2018 | -9.44 |
| Q1 2018 | -8.61 |
| Q4 2017 | -8.04 |
| Q2 2017 | 0.00 |
| Q1 2017 | 0.00 |
| Q4 2016 | 0.00 |
| Q4 2015 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.427B | $0.023B |
| Quanterix Corporation is a developer of tools in high definition diagnostics. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology. It offers Simoa consumables, which include Simoa Discs, Simoa Cuvettes, Simoa Sealing Oil, Simoa Buffers and Disposable Tips. The company services include Simoa Accelerator Lab and custom assay development services. Quanterix Corporation is based in LEXINGTON, United States. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medtronic (MDT) | Ireland | $132.148B | 20.26 |
| Abbott Laboratories (ABT) | United States | $121.136B | 25.39 |
| Stryker (SYK) | United States | $65.261B | 25.22 |
| Boston Scientific (BSX) | United States | $52.233B | 27.17 |
| Baxter (BAX) | United States | $41.336B | 28.14 |
| Zimmer Biomet Holdings (ZBH) | United States | $26.744B | 17.18 |
| ResMed (RMD) | United States | $16.242B | 32.25 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.130B | 0.00 |
| Canopy Growth (CGC) | Canada | $11.376B | 0.00 |
| Perrigo (PRGO) | Ireland | $10.065B | 14.28 |
| Bio-Rad Laboratories (BIO) | United States | $8.905B | 57.18 |
| Hill-Rom Holdings (HRC) | United States | $6.065B | 20.57 |
| Insulet (PODD) | United States | $6.029B | 0.00 |
| Haemonetics (HAE) | United States | $5.767B | 52.63 |
| ICU Medical (ICUI) | United States | $5.434B | 36.82 |
| Neogen (NEOG) | United States | $4.634B | 73.73 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $4.582B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $4.266B | 0.00 |
| Hutchison China MediTech (HCM) | China | $3.798B | 0.00 |
| NuVasive (NUVA) | United States | $3.542B | 33.60 |
| National Vision Holdings (EYE) | United States | $3.271B | 72.23 |
| Quidel (QDEL) | United States | $2.532B | 51.87 |
| NxStage Medical (NXTM) | United States | $1.847B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.708B | 24.31 |
| AtriCure (ATRC) | United States | $1.247B | 0.00 |
| Cardiovascular Systems (CSII) | United States | $1.233B | 735.80 |
| Omeros (OMER) | United States | $1.216B | 0.00 |
| VAREX IMAGING (VREX) | United States | $1.138B | 18.60 |
| Owens & Minor (OMI) | United States | $1.069B | 11.44 |
| PetIQ (PETQ) | United States | $1.069B | 34.97 |
| Eagle Pharmaceuticals (EGRX) | United States | $1.015B | 29.95 |
| Cerus (CERS) | United States | $0.985B | 0.00 |
| Surmodics (SRDX) | United States | $0.972B | 117.42 |
| MacroGenics (MGNX) | United States | $0.938B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.938B | 61.32 |
| TG Therapeutics (TGTX) | United States | $0.745B | 0.00 |
| Insys Therapeutics (INSY) | United States | $0.679B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.667B | 32.00 |
| Meridian Bioscience (VIVO) | United States | $0.642B | 21.96 |
| Lantheus Holdings (LNTH) | United States | $0.599B | 18.63 |
| Evolus (EOLS) | United States | $0.502B | 0.00 |
| NanoString Technologies (NSTG) | United States | $0.499B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.423B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.357B | 22.97 |
| Surface Oncology (SURF) | United States | $0.332B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.286B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.228B | 0.00 |
| Chimerix (CMRX) | United States | $0.191B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.172B | 0.00 |
| Fonar (FONR) | United States | $0.155B | 7.73 |
| Chembio Diagnostics (CEMI) | United States | $0.135B | 0.00 |
| Female Health (VERU) | United States | $0.099B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | Israel | $0.085B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.082B | 24.50 |
| United-Guardian (UG) | United States | $0.076B | 16.62 |
| Neurotrope (NTRP) | United States | $0.066B | 0.00 |
| Imprimis Pharmaceuticals (IMMY) | United States | $0.059B | 0.00 |
| CAS Medical Systems (CASM) | United States | $0.057B | 0.00 |
| ImmuCell (ICCC) | United States | $0.049B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.033B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.025B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.024B | 0.00 |
| Senestech (SNES) | United States | $0.019B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
